InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,484.62
(
0.21%
)
US TECH 100
19,404.40
(
0.01%
)
Dow Jones
38,825.60
(
0.12%
)
Brent Oil
84.74
(
1.00%
)
Bitcoin
64,226.38
(
-3.40%
)
Post# of 252248
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: masterlongevity post# 148716

Thursday, 09/13/2012 3:53:20 AM

Thursday, September 13, 2012 3:53:20 AM

Post# of 252248
I guess you're right on the "meta-analysis of a subgroup" issue, but perhaps an ADAS-Cog change of >=3 for solanezumab in the prespecified secondary analysis of pooled mild along with MRI and biomarkers, could give them a shot with the FDA considering the highly unmet need and the good safety profile. A 3 point change seems quite hypothetical though...
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up